{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:23:54Z","timestamp":1763018634871},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-023-05550-6","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:01:43Z","timestamp":1700672503000},"page":"2591-2600","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Research progress of additional pathogenic mutations in chronic neutrophilic leukemia"],"prefix":"10.1007","volume":"103","author":[{"given":"Jiapei","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"issue":"4","key":"5550_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/ajh.26481","volume":"97","author":"N Szuber","year":"2022","unstructured":"Szuber N, Elliott M, Tefferi A (2022) Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management. Am J Hematol 97(4):491\u2013505. https:\/\/doi.org\/10.1002\/ajh.26481","journal-title":"Am J Hematol"},{"issue":"19","key":"5550_CR2","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","volume":"368","author":"JE Maxson","year":"2013","unstructured":"Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 368(19):1781\u20131790. https:\/\/doi.org\/10.1056\/NEJMoa1214514","journal-title":"N Engl J Med"},{"issue":"9","key":"5550_CR3","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/leu.2013.122","volume":"27","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, Ketterling RP, Maxson JE, Tyner JW, Tefferi A (2013) CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 27(9):1870\u20131873. https:\/\/doi.org\/10.1038\/leu.2013.122","journal-title":"Leukemia"},{"issue":"20","key":"5550_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"6","key":"5550_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1182\/blood-2016-10-695981","volume":"129","author":"JE Maxson","year":"2017","unstructured":"Maxson JE, Tyner JW (2017) Genomics of chronic neutrophilic leukemia. Blood 129(6):715\u2013722. https:\/\/doi.org\/10.1182\/blood-2016-10-695981","journal-title":"Blood"},{"issue":"9","key":"5550_CR6","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1074\/jbc.M113.508440","volume":"289","author":"JE Maxson","year":"2014","unstructured":"Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW (2014) Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. J Biol Chem 289(9):5820\u20135827. https:\/\/doi.org\/10.1074\/jbc.M113.508440","journal-title":"J Biol Chem"},{"issue":"1","key":"5550_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbrc.2019.12.030","volume":"523","author":"A Price","year":"2020","unstructured":"Price A, Druhan LJ, Lance A, Clark G, Vestal CG, Zhang Q, Foureau D, Parsons J, Hamilton A, Steuerwald NM, Avalos BR (2020) T618I CSF3R mutations in chronic neutrophilic leukemia induce oncogenic signals through aberrant trafficking and constitutive phosphorylation of the O-glycosylated receptor form. Biochem Biophys Res Commun 523(1):208\u2013213. https:\/\/doi.org\/10.1016\/j.bbrc.2019.12.030","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"5550_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-018-0058-7","volume":"8","author":"N Szuber","year":"2018","unstructured":"Szuber N, Finke CM, Lasho TL, Elliott MA, Hanson CA, Pardanani A, Tefferi A (2018) CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. Blood Cancer J 8(2):21. https:\/\/doi.org\/10.1038\/s41408-018-0058-7","journal-title":"Blood Cancer J"},{"issue":"2","key":"5550_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF00321039","volume":"54","author":"DK Hossfeld","year":"1987","unstructured":"Hossfeld DK, Lokhorst HW, Garbrecht M (1987) Neutrophilic leukemia accompanied by hemorrhagic diathesis: report of two cases. Blut 54(2):109\u2013113. https:\/\/doi.org\/10.1007\/BF00321039","journal-title":"Blut"},{"issue":"4","key":"5550_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/BF02982088","volume":"74","author":"T Noguchi","year":"2001","unstructured":"Noguchi T, Ikeda K, Yamamoto K, Ashiba A, Yoshida J, Munemasa M, Takenaka K, Shinagawa K, Ishimaru F, Yoshino T, Niiya K, Harada M (2001) Severe bleeding tendency caused by leukemic infiltration and destruction of vascular walls in chronic neutrophilic leukemia. Int J Hematol 74(4):437\u2013441. https:\/\/doi.org\/10.1007\/BF02982088","journal-title":"Int J Hematol"},{"issue":"4","key":"5550_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2169\/internalmedicine.55.5059","volume":"55","author":"T Mitsumori","year":"2016","unstructured":"Mitsumori T, Komatsu N, Kirito K (2016) A CSF3R T618I Mutation in a patient with chronic neutrophilic leukemia and severe bleeding complications. Intern Med 55(4):405\u2013407. https:\/\/doi.org\/10.2169\/internalmedicine.55.5059","journal-title":"Intern Med"},{"issue":"22","key":"5550_CR12","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","volume":"122","author":"AG Fleischman","year":"2013","unstructured":"Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW (2013) The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood 122(22):3628\u20133631. https:\/\/doi.org\/10.1182\/blood-2013-06-509976","journal-title":"Blood"},{"issue":"24","key":"5550_CR13","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.12998\/wjcc.v8.i24.6337","volume":"8","author":"YP Li","year":"2020","unstructured":"Li YP, Chen N, Ye XM, Xia YS (2020) Eighty-year-old man with rare chronic neutrophilic leukemia caused by CSF3R T618I mutation: a case report and review of literature. World J Clin Cases 8(24):6337\u20136345. https:\/\/doi.org\/10.12998\/wjcc.v8.i24.6337","journal-title":"World J Clin Cases"},{"issue":"8","key":"5550_CR14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.revmed.2020.03.012","volume":"41","author":"L Talon","year":"2020","unstructured":"Talon L, de Renzis B, Fiore M, Sanhes L, Sapin AF, Berger M, Sinegre T, Lebreton A (2020) Fatal intracerebral hemorrhage in a patient with chronic neutrophilic leukemia: about one case and literature review. Rev Med Interne 41(8):552\u2013558. https:\/\/doi.org\/10.1016\/j.revmed.2020.03.012","journal-title":"Rev Med Interne"},{"issue":"21","key":"5550_CR15","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.1182\/bloodadvances.2020003109","volume":"4","author":"CS Boddy","year":"2020","unstructured":"Boddy CS, Tan BT, Aoki J (2020) B-lymphoblastic leukemia arising in a patient with chronic neutrophilic leukemia. Blood Adv 4(21):5389\u20135392. https:\/\/doi.org\/10.1182\/bloodadvances.2020003109","journal-title":"Blood Adv"},{"issue":"10","key":"5550_CR16","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","volume":"122","author":"J Gotlib","year":"2013","unstructured":"Gotlib J, Maxson JE, George TI, Tyner JW (2013) The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood 122(10):1707\u20131711. https:\/\/doi.org\/10.1182\/blood-2013-05-500959","journal-title":"Blood"},{"issue":"12","key":"5550_CR17","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","volume":"99","author":"M Meggendorfer","year":"2014","unstructured":"Meggendorfer M, Haferlach T, Alpermann T, Jeromin S, Haferlach C, Kern W, Schnittger S (2014) Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica 99(12):e244-246. https:\/\/doi.org\/10.3324\/haematol.2014.113159","journal-title":"Haematologica"},{"issue":"7","key":"5550_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ajh.24031","volume":"90","author":"MA Elliott","year":"2015","unstructured":"Elliott MA, Pardanani A, Hanson CA, Lasho TL, Finke CM, Belachew AA, Tefferi A (2015) ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hematol 90(7):653\u2013656. https:\/\/doi.org\/10.1002\/ajh.24031","journal-title":"Am J Hematol"},{"issue":"13","key":"5550_CR19","doi-asserted-by":"publisher","first-page":"20834","DOI":"10.18632\/oncotarget.15355","volume":"8","author":"Y Ouyang","year":"2017","unstructured":"Ouyang Y, Qiao C, Chen Y, Zhang SJ (2017) Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia. Oncotarget 8(13):20834\u201320841. https:\/\/doi.org\/10.18632\/oncotarget.15355","journal-title":"Oncotarget"},{"issue":"1","key":"5550_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3760\/cma.j.issn.0253-2727.2017.01.006","volume":"38","author":"YJ Cui","year":"2017","unstructured":"Cui YJ, Jiang Q, Liu JQ, Li B, Xu ZF, Qin TJ, Zhang Y, Cai WY, Zhang HL, Fang LW, Pan LJ, Hu NB, Qu SQ, Xiao ZJ (2017) The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia. Zhonghua Xue Ye Xue Za Zhi 38(1):28\u201332. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2017.01.006","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"11","key":"5550_CR21","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood.2019000611","volume":"134","author":"H Zhang","year":"2019","unstructured":"Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW (2019) Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 134(11):867\u2013879. https:\/\/doi.org\/10.1182\/blood.2019000611","journal-title":"Blood"},{"issue":"10","key":"5550_CR22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1200\/JCO.19.00895","volume":"38","author":"KT Dao","year":"2020","unstructured":"Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister A, Schultz SS, Stevens BC, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW (2020) Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia. J Clin Oncol 38(10):1006\u20131018. https:\/\/doi.org\/10.1200\/JCO.19.00895","journal-title":"J Clin Oncol"},{"issue":"1","key":"5550_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.19746\/j.cnki.issn.1009-2137.2020.01.014","volume":"28","author":"YJ Guo","year":"2020","unstructured":"Guo YJ, Wang Y, Wang LH, Zuo YB, Niu ZY, Lin FR, Zhang JY (2020) Analysis of clinical features and prognosis of patients with chronic neutrophil leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 28(1):82\u201387. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2020.01.014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"9","key":"5550_CR24","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1182\/bloodadvances.2022008204","volume":"7","author":"G Carreno-Tarragona","year":"2023","unstructured":"Carreno-Tarragona G, Alvarez-Larran A, Harrison C, Martinez-Avila JC, Hernandez-Boluda JC, Ferrer-Marin F, Radia DH, Mora E, Francis S, Gonzalez-Martinez T, Goddard K, Perez-Encinas M, Narayanan S, Raya JM, Singh V, Gutierrez X, Toth P, Amat-Martinez P, McIlwaine L, Alobaidi M, Mayani K, McGregor A, Stuckey R, Psaila B, Segura A, Alvares C, Davidson K, Osorio S, Cutting R, Sweeney CP, Rufian L, Moreno L, Cuenca I, Smith J, Morales ML, Gil-Manso R, Koutsavlis I, Wang L, Mead AJ, Rozman M, Martinez-Lopez J, Ayala R, Cross NCP (2023) CNL and aCML should be considered as a single entity based on molecular profiles and outcomes. Blood Adv 7(9):1672\u20131681. https:\/\/doi.org\/10.1182\/bloodadvances.2022008204","journal-title":"Blood Adv"},{"key":"5550_CR25","doi-asserted-by":"publisher","first-page":"891961","DOI":"10.3389\/fonc.2022.891961","volume":"12","author":"TP Thomopoulos","year":"2022","unstructured":"Thomopoulos TP, Symeonidis A, Kourakli A, Papageorgiou SG, Pappa V (2022) Chronic neutrophilic leukemia: a comprehensive review of clinical characteristics, genetic landscape and management. Front Oncol 12:891961. https:\/\/doi.org\/10.3389\/fonc.2022.891961","journal-title":"Front Oncol"},{"issue":"3","key":"5550_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/1535-7163.MCT-11-0505","volume":"11","author":"J Jing","year":"2012","unstructured":"Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, Degenhardt Y (2012) Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11(3):720\u2013729. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0505","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"5550_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12094-017-1722-2","volume":"20","author":"SE Langabeer","year":"2018","unstructured":"Langabeer SE, Haslam K, Kelly J, Quinn J, Morrell R, Conneally E (2018) Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. Clin Transl Oncol 20(3):420\u2013423. https:\/\/doi.org\/10.1007\/s12094-017-1722-2","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"5550_CR28","doi-asserted-by":"publisher","first-page":"e24287","DOI":"10.1002\/jcla.24287","volume":"36","author":"JP Gao","year":"2022","unstructured":"Gao JP, Zhai LJ, Gao XH, Min FL (2022) Chronic neutrophilic leukemia complicated with monoclonal gammopathy of undetermined significance: a case report and literature review. J Clin Lab Anal 36(4):e24287. https:\/\/doi.org\/10.1002\/jcla.24287","journal-title":"J Clin Lab Anal"},{"issue":"6","key":"5550_CR29","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/s41375-019-0688-1","volume":"34","author":"RC Stoner","year":"2020","unstructured":"Stoner RC, Press RD, Maxson JE, Tyner JW, Dao KT (2020) Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy. Leukemia 34(6):1684\u20131688. https:\/\/doi.org\/10.1038\/s41375-019-0688-1","journal-title":"Leukemia"},{"issue":"3","key":"5550_CR30","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00431-019-03468-8","volume":"179","author":"Y Miao","year":"2020","unstructured":"Miao Y, Li B, Ding L, Zhu H, Luo C, Wang J, Luo C, Chen J (2020) PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center. Eur J Pediatr 179(3):463\u2013472. https:\/\/doi.org\/10.1007\/s00431-019-03468-8","journal-title":"Eur J Pediatr"},{"key":"5550_CR31","doi-asserted-by":"publisher","unstructured":"Mayerhofer C, Niemeyer CM, Flotho C (2021) Current treatment of juvenile myelomonocytic leukemia. J Clin Med 10 (14). https:\/\/doi.org\/10.3390\/jcm10143084","DOI":"10.3390\/jcm10143084"},{"key":"5550_CR32","doi-asserted-by":"publisher","first-page":"106384","DOI":"10.1016\/j.leukres.2020.106384","volume":"94","author":"X Wang","year":"2020","unstructured":"Wang X, Resendes NM, Shanahan L, Hutchinson L, Woda B, Cerny J (2020) Chronic neutrophilic leukemia, a rare case of leukocytosis. Leuk Res 94:106384. https:\/\/doi.org\/10.1016\/j.leukres.2020.106384","journal-title":"Leuk Res"},{"issue":"Suppl 2","key":"5550_CR33","doi-asserted-by":"publisher","first-page":"S330","DOI":"10.1016\/S2152-2650(22)01447-1","volume":"22","author":"AN Kirienko","year":"2022","unstructured":"Kirienko AN, Motyko EV, Kustova DV, Efremova EV, Morozova EV, Shikhbabaeva DI, Vinogradova OY, Semenova NY, Enukashvily NI, Shuvaev VA, Voloshin SV, Sidorkevich SV, Martynkevich IS (2022) MPN-225 next generation sequencing (NGS) in the diagnosis, prognosis and features of the disease in Ph-negative myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S330\u2013S331. https:\/\/doi.org\/10.1016\/S2152-2650(22)01447-1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"5550_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12288-012-0203-6","volume":"30","author":"S Gajendra","year":"2014","unstructured":"Gajendra S, Gupta R, Chandgothia M, Kumar L, Gupta R, Chavan SM (2014) Chronic neutrophilic leukemia with V617F JAK2 mutation. Indian J Hematol Blood Transfus 30(2):139\u2013142. https:\/\/doi.org\/10.1007\/s12288-012-0203-6","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"5550_CR35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1080\/16078454.2019.1642554","volume":"24","author":"B Yin","year":"2019","unstructured":"Yin B, Chen X, Gao F, Li J, Wang HW (2019) Analysis of gene mutation characteristics in patients with chronic neutrophilic leukaemia. Hematology 24(1):538\u2013543. https:\/\/doi.org\/10.1080\/16078454.2019.1642554","journal-title":"Hematology"},{"key":"5550_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05376-2","author":"J Gao","year":"2023","unstructured":"Gao J, Gao J, Min F (2023) Chronic neutrophilic leukemia with JAK2 mutation: is it true chronic neutrophilic leukemia? Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-023-05376-2","journal-title":"Ann Hematol"},{"issue":"1","key":"5550_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W (2020) EZH2: a novel target for cancer treatment. J Hematol Oncol 13(1):104. https:\/\/doi.org\/10.1186\/s13045-020-00937-8","journal-title":"J Hematol Oncol"},{"issue":"6","key":"5550_CR38","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s11899-018-0491-5","volume":"13","author":"B Li","year":"2018","unstructured":"Li B, Mascarenhas JO, Rampal RK (2018) Leukemic transformation of myeloproliferative neoplasms: therapeutic and genomic considerations. Curr Hematol Malig Rep 13(6):588\u2013595. https:\/\/doi.org\/10.1007\/s11899-018-0491-5","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"5550_CR39","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/bjh.14456","volume":"180","author":"Q Luo","year":"2018","unstructured":"Luo Q, Shen J, Yang Y, Tang H, Shi M, Liu J, Liu Z, Shi X, Yi Y (2018) CSF3R T618I, ASXL1 G942 fs and STAT5B N642H trimutation co-contribute to a rare chronic neutrophilic leukaemia manifested by rapidly progressive leucocytosis, severe infections, persistent fever and deep venous thrombosis. Br J Haematol 180(6):892\u2013894. https:\/\/doi.org\/10.1111\/bjh.14456","journal-title":"Br J Haematol"},{"issue":"2","key":"5550_CR40","doi-asserted-by":"publisher","first-page":"e0171608","DOI":"10.1371\/journal.pone.0171608","volume":"12","author":"LH Shou","year":"2017","unstructured":"Shou LH, Cao D, Dong XH, Fang Q, Wu Y, Zhang Y, Fei JP, Xu BL (2017) Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: a meta-analysis. PLoS ONE 12(2):e0171608. https:\/\/doi.org\/10.1371\/journal.pone.0171608","journal-title":"PLoS ONE"},{"issue":"2","key":"5550_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3760\/cma.j.issn.0253-3766.2020.02.005","volume":"42","author":"WS Zheng","year":"2020","unstructured":"Zheng WS, Guan LX, Cheng LC, Hu YL, Xu YY, Yang T, Peng B, Wu YL, Bo J, Wang QS, Gao XN (2020) Ruxolitinib in the treatment of two cases of chronic neutrophilic leukemia. Zhonghua Zhong Liu Za Zhi 42(2):113\u2013114. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2020.02.005","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"2","key":"5550_CR42","doi-asserted-by":"publisher","first-page":"522","DOI":"10.19746\/j.cnki.issn.1009-2137.2022.02.033","volume":"30","author":"ZQ Wang","year":"2022","unstructured":"Wang ZQ, Li YJ, Wang DH, Yang EP, Li YM, Niu JC, Sun MQ, Chen Z, Liu WY, Hu XM (2022) Analysis of DNA methylation gene mutations and clinical features in patients with myeloproliferative neoplasm. Zhongguo Shi Yan Xue Ye Xue Za Zhi 30(2):522\u2013528. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2022.02.033","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"3","key":"5550_CR43","first-page":"12","volume":"12","author":"E Abedi","year":"2021","unstructured":"Abedi E, Ramzi M, Karimi M, Yaghobi R, Mohammadi H, Bayat E, Moghadam M, Farokhian F, Dehghani M, Golafshan HA, Haghpanah S (2021) TET2, DNMT3A, IDH1, and JAK2 mutation in myeloproliferative neoplasms in southern Iran. Int J Organ Transplant Med 12(3):12\u201320","journal-title":"Int J Organ Transplant Med"},{"key":"5550_CR44","doi-asserted-by":"publisher","unstructured":"Chia YC, Islam MA, Hider P, Woon PY, Johan MF, Hassan R, Ramli M (2021) The prevalence of TET2 gene mutations in patients with BCR-ABL-negative myeloproliferative neoplasms (MPN): a systematic review and meta-analysis. Cancers (Basel) 13 (12). https:\/\/doi.org\/10.3390\/cancers13123078","DOI":"10.3390\/cancers13123078"},{"issue":"1","key":"5550_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/16078454.2019.1613291","volume":"24","author":"QG Zhang","year":"2019","unstructured":"Zhang QG, Wang J, Gong WY, Jing QC (2019) Clonal evolution in a chronic neutrophilic leukemia patient. Hematology 24(1):455\u2013458. https:\/\/doi.org\/10.1080\/16078454.2019.1613291","journal-title":"Hematology"},{"issue":"2","key":"5550_CR46","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00277-020-04152-w","volume":"100","author":"A Hinze","year":"2021","unstructured":"Hinze A, Rinke J, Hochhaus A, Ernst T (2021) Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation. Ann Hematol 100(2):581\u2013584. https:\/\/doi.org\/10.1007\/s00277-020-04152-w","journal-title":"Ann Hematol"},{"issue":"11","key":"5550_CR47","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1042\/BCJ20160632","volume":"474","author":"E Deltcheva","year":"2017","unstructured":"Deltcheva E, Nimmo R (2017) RUNX transcription factors at the interface of stem cells and cancer. Biochem J 474(11):1755\u20131768. https:\/\/doi.org\/10.1042\/BCJ20160632","journal-title":"Biochem J"},{"issue":"2","key":"5550_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.14348\/molcells.2019.0252","volume":"43","author":"A Yokota","year":"2020","unstructured":"Yokota A, Huo L, Lan F, Wu J, Huang G (2020) The clinical, molecular, and mechanistic basis of RUNX1 mutations identified in hematological malignancies. Mol Cells 43(2):145\u2013152. https:\/\/doi.org\/10.14348\/molcells.2019.0252","journal-title":"Mol Cells"},{"issue":"15","key":"5550_CR49","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood-2016-09-687889","volume":"129","author":"JD Crispino","year":"2017","unstructured":"Crispino JD, Horwitz MS (2017) GATA factor mutations in hematologic disease. Blood 129(15):2103\u20132110. https:\/\/doi.org\/10.1182\/blood-2016-09-687889","journal-title":"Blood"},{"issue":"5","key":"5550_CR50","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.3324\/haematol.2016.163089","volume":"102","author":"Z Nooruddin","year":"2017","unstructured":"Nooruddin Z, Miltgen N, Wei Q, Schowinsky J, Pan Z, Tobin J, Purev E, Gutman JA, Robinson W, Pollyea DA (2017) Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. Haematologica 102(5):e207\u2013e209. https:\/\/doi.org\/10.3324\/haematol.2016.163089","journal-title":"Haematologica"},{"key":"5550_CR51","doi-asserted-by":"publisher","unstructured":"Will CL, Luhrmann R (2011) Spliceosome structure and function. Cold Spring Harb Perspect Biol 3 (7). https:\/\/doi.org\/10.1101\/cshperspect.a003707","DOI":"10.1101\/cshperspect.a003707"},{"issue":"1","key":"5550_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wrna.1141","volume":"4","author":"JJ Turunen","year":"2013","unstructured":"Turunen JJ, Niemela EH, Verma B, Frilander MJ (2013) The significant other: splicing by the minor spliceosome. Wiley Interdiscip Rev RNA 4(1):61\u201376. https:\/\/doi.org\/10.1002\/wrna.1141","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"16","key":"5550_CR53","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood.2019004229","volume":"136","author":"L Palomo","year":"2020","unstructured":"Palomo L, Meggendorfer M, Hutter S, Twardziok S, Adema V, Fuhrmann I, Fuster-Tormo F, Xicoy B, Zamora L, Acha P, Kerr CM, Kern W, Maciejewski JP, Sole F, Haferlach C, Haferlach T (2020) Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms. Blood 136(16):1851\u20131862. https:\/\/doi.org\/10.1182\/blood.2019004229","journal-title":"Blood"},{"issue":"4","key":"5550_CR54","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/ejh.13579","volume":"106","author":"S Bartels","year":"2021","unstructured":"Bartels S, Vogtmann J, Schipper E, Busche G, Schlue J, Lehmann U, Kreipe H (2021) Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression. Eur J Haematol 106(4):520\u2013528. https:\/\/doi.org\/10.1111\/ejh.13579","journal-title":"Eur J Haematol"},{"issue":"11","key":"5550_CR55","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.medcli.2014.03.020","volume":"144","author":"A Senin","year":"2015","unstructured":"Senin A, Arenillas L, Martinez-Aviles L, Fernandez-Rodriguez C, Bellosillo B, Florensa L, Besses C, Alvarez-Larran A (2015) Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia. Med Clin (Barc) 144(11):487\u2013490. https:\/\/doi.org\/10.1016\/j.medcli.2014.03.020","journal-title":"Med Clin (Barc)"},{"issue":"6","key":"5550_CR56","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00277-021-04491-2","volume":"100","author":"Y Qian","year":"2021","unstructured":"Qian Y, Chen Y, Li X (2021) CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia. Ann Hematol 100(6):1459\u20131461. https:\/\/doi.org\/10.1007\/s00277-021-04491-2","journal-title":"Ann Hematol"},{"issue":"5","key":"5550_CR57","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.3324\/haematol.2017.183160","volume":"103","author":"M Meggendorfer","year":"2018","unstructured":"Meggendorfer M, Jeromin S, Haferlach C, Kern W, Haferlach T (2018) The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms. Haematologica 103(5):e192\u2013e195. https:\/\/doi.org\/10.3324\/haematol.2017.183160","journal-title":"Haematologica"},{"issue":"6","key":"5550_CR58","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood.2021014777","volume":"140","author":"SA Carratt","year":"2022","unstructured":"Carratt SA, Kong GL, Curtiss BM, Schonrock Z, Maloney L, Maniaci BN, Blaylock HZ, Baris A, Druker BJ, Braun TP, Maxson JE (2022) Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms. Blood 140(6):644\u2013658. https:\/\/doi.org\/10.1182\/blood.2021014777","journal-title":"Blood"},{"key":"5550_CR59","doi-asserted-by":"publisher","unstructured":"Marneth AE, Mullally A (2020) The molecular genetics of myeloproliferative neoplasms. Cold Spring Harb Perspect Med 10 (2). https:\/\/doi.org\/10.1101\/cshperspect.a034876","DOI":"10.1101\/cshperspect.a034876"},{"issue":"7","key":"5550_CR60","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1412098","volume":"372","author":"CA Ortmann","year":"2015","unstructured":"Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitropoulou D, Guglielmelli P, Bellosillo B, Besses C, Dohner K, Harrison CN, Vassiliou GS, Vannucchi A, Campbell PJ, Green AR (2015) Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 372(7):601\u2013612. https:\/\/doi.org\/10.1056\/NEJMoa1412098","journal-title":"N Engl J Med"},{"issue":"11","key":"5550_CR61","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","volume":"100","author":"J Nangalia","year":"2015","unstructured":"Nangalia J, Nice FL, Wedge DC, Godfrey AL, Grinfeld J, Thakker C, Massie CE, Baxter J, Sewell D, Silber Y, Campbell PJ, Green AR (2015) DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica 100(11):e438-442. https:\/\/doi.org\/10.3324\/haematol.2015.129510","journal-title":"Haematologica"},{"issue":"11","key":"5550_CR62","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.21873\/anticanres.13837","volume":"39","author":"JM Byun","year":"2019","unstructured":"Byun JM, Song S, Koh Y, Yoon SS, Kim D (2019) The temporal sequence and the differences in somatic mutation acquisition determines clinical behaviors of JAK2-positive myeloproliferative neoplasms. Anticancer Res 39(11):6273\u20136282. https:\/\/doi.org\/10.21873\/anticanres.13837","journal-title":"Anticancer Res"},{"issue":"6","key":"5550_CR63","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/leu.2014.39","volume":"28","author":"TL Lasho","year":"2014","unstructured":"Lasho TL, Mims A, Elliott MA, Finke C, Pardanani A, Tefferi A (2014) Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia 28(6):1363\u20131365. https:\/\/doi.org\/10.1038\/leu.2014.39","journal-title":"Leukemia"},{"issue":"4","key":"5550_CR64","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ajh.2830430416","volume":"43","author":"S Meyer","year":"1993","unstructured":"Meyer S, Feremans W, Cantiniaux B, Capel P, Huygen K, Dicato M (1993) Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia. Am J Hematol 43(4):307\u2013309. https:\/\/doi.org\/10.1002\/ajh.2830430416","journal-title":"Am J Hematol"},{"issue":"1","key":"5550_CR65","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000345851","volume":"130","author":"X Zhang","year":"2013","unstructured":"Zhang X, Pan J, Guo J (2013) Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon alpha-2b. Acta Haematol 130(1):44\u201346. https:\/\/doi.org\/10.1159\/000345851","journal-title":"Acta Haematol"},{"issue":"7","key":"5550_CR66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11864-021-00856-x","volume":"22","author":"N Szuber","year":"2021","unstructured":"Szuber N, Tefferi A (2021) Current management of chronic neutrophilic leukemia. Curr Treat Options Oncol 22(7):59. https:\/\/doi.org\/10.1007\/s11864-021-00856-x","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"5550_CR67","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3760\/cma.j.issn.0253-2727.2018.12.012","volume":"39","author":"NB Hu","year":"2018","unstructured":"Hu NB, Fang LW, Qin TJ, Xiao ZJ, Xu ZF (2018) Ruxolitinib for chronic neutrophilic leukemia: a case report and literature review. Zhonghua Xue Ye Xue Za Zhi 39(12):1029\u20131032. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2018.12.012","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"7414","key":"5550_CR68","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature11303","volume":"489","author":"P Koppikar","year":"2012","unstructured":"Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gonen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL (2012) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489(7414):155\u2013159. https:\/\/doi.org\/10.1038\/nature11303","journal-title":"Nature"},{"issue":"12","key":"5550_CR69","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/cncr.29986","volume":"122","author":"G Borthakur","year":"2016","unstructured":"Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H (2016) Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer 122(12):1871\u20131879. https:\/\/doi.org\/10.1002\/cncr.29986","journal-title":"Cancer"},{"issue":"4","key":"5550_CR70","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/bjh.18297","volume":"198","author":"B Dholaria","year":"2022","unstructured":"Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hernandez-Boluda JC, Czerw T, Hayden PJ, Kansagra A, Ho VT, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani BN, McLornan D, Yakoub-Agha I, Saber W (2022) Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: a combined CIBMTR\/CMWP of EBMT analysis. Br J Haematol 198(4):785\u2013789. https:\/\/doi.org\/10.1111\/bjh.18297","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05550-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05550-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05550-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T17:01:57Z","timestamp":1722099717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05550-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5550"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05550-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable since the manuscript does not contain any patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}